100% Quality Guarantee
PhD-Level Technical Support
Key Features

Crizanlizumab Biosimilar (SELP) Antibody (HDBS0071)

SKU HDBS0071
Antibody Type Biosimilar Reference Antibody
Applications IHC
Applications FC
Applications Drug Development
Applications Pharmacokinetics
Disease Area Cancer
Protein SELP
Reactivity Human
Host Species Human
Isotype IgG2
€431

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheet

Crizanlizumab Biosimilar (SELP) Antibody (HDBS0071)

The Anti-SELPL Crizanlizu Biosimilar (HDBS0071) is a cutting-edge product designed for research purposes involving the SELPL protein. SELPL, also known as P-selectin, is a cell adhesion molecule that plays a critical role in mediating the adhesion of leukocytes to endothelial cells during inflammation. This biosimilar antibody, manufactured using advanced technology, offers high specificity and sensitivity for detecting SELPL in various samples.Developed for researchers in the fields of immunology and inflammation, the Anti-SELPL Crizanlizu Biosimilar (HDBS0071) enables precise detection and analysis of SELPL expression levels in cell types relevant to these research areas.

With its unique ability to bind selectively to SELPL, this biosimilar antibody facilitates the investigation of SELPL's involvement in immune responses and inflammatory processes.By providing researchers with a reliable tool for studying SELPL, the Anti-SELPL Crizanlizu Biosimilar (HDBS0071) holds promise for advancing our understanding of immune regulation and inflammatory diseases. Its use in studies involving conditions such as vascular inflammation and thrombosis could pave the way for the development of novel therapies targeting SELPL and its associated pathways.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose